Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis

Rheumatology

Volumn 39, Issue 11, 2000, Pages 1255-1262

  Nagashima, M ^a   Wauke, K ^a   Hirano, D ^a   Ishigami, S ^a   Aono, H ^b   Takai, M ^b   Sasano, M ^b   Yoshino, S ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Basic fibroblast growth factor; Disease modifying anti rheumatic drugs; Rheumatoid arthritis; Vascular endothelial growth factor

Indexed keywords

ANTIRHEUMATIC AGENT; AUROTHIOMALATE; BASIC FIBROBLAST GROWTH FACTOR; BUCILLAMINE; DEXAMETHASONE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; VASCULOTROPIN;

ARTICLE; BLOOD LEVEL; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

EID: 0033709917     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/39.11.1255     Document Type: Article

References (47)

1. Angiogenesis
2. Vascular endothelial growth factor is a secreted angiogenic mitogen
3. Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints
4. Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease
5. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid synovium
6. Production of platelet derived growth factor B chain (PDGF-B/c-sis) mRNA and immunoreactive PDGF B-like polypeptide by rheumatoid synovium: Coexpression with heparin binding acidic fibroblast growth factor-1
7. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
8. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis
9. Expression of vascular endothelial growth factor in capillary hemangioblastoma
10. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
11. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
12. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis
13. Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis: Detection by immuno-histological staining and in situ hybridization
14. Synoviocytes synthesize, bind and respond to basic fibroblast growth factor
15. Expression and functional expansion of fibroblast growth factor receptor T cells in rheumatoid synovium and peripheral blood of patients with rheumatoid arthritis
16. Immunosuppression by the disease modifying antirheumatic drug bucillamine: Inhibition of human T lymphocyte function by bucillamine and its metabolites
17. Effects of gold sodium thiomalate on interferon stimulation of C2 synthesis and HLA-DR expression by human monocytes
18. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis
19. Mechanism of action of methotrexate: Experimental evidence that methotrexate blocks the binding of interleukin-1b to the interleukin-1 receptor on target cells
20. Interleukin-8 in inflammatory rheumatic diseases: Synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate
21. Methotrexate action in rheumatoid arthritis: Stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells
22. Sulfasalazine inhibition of human granulocyte activation by inhibition of second messenger compounds
23. Inhibitory effects of sulfasalazine and related compounds on superoxide production by human polymorphonuclear lymphocytes
24. Inhibition of production of macrophage-derived angiogenic activity by the anti-rheumatic agents gold sodium thiomalate and auranofin
25. Effects of disease modifying antirheumatic drugs (DMARDs) and DEX on IL-1β and IL-6 production by IL-1β stimulated synovial culture cells
26. Inhibition of human endothelial cell proliferation by gold compounds
27. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low dose methotrexate
28. Control of oxidative damage in rheumatoid arthritis by gold(I)-thiolate drugs
29. Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine
30. Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells
31. Spontaneous production of an interleukin-1-like factor by cloned rheumatoid synovial cells in long-term culture
32. Direct suppression of human synovial cell proliferation in vitro by salazosulfapyridine and bucillamine
33. Angiogenesis
34. Outcome in patients with rheumatoid arthritis treated according to the 'sawtooth' strategy
35. Auranofin treatment in early rheumatoid arthritis may postpone early retirement: Results from a 2-year double blind trial
36. Effect of gold on progression of erosions in rheumatoid arthritis: Better results with early treatment
37. Methotrexate and sulfasalazine combination therapy: Is it worth the risk?
38. Interleukin-6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate
39. Effect of DMARDs on IL-6, bFGF and VEGF in cultured synovial cells-basic research on combination therapy
40. The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine
41. Inhibition of TNF-α expression by adenosine: Role of A3 adenosine receptors
42. Molecular therapeutics: Methotrexate and its mechanism of action
43. The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis
44. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritis
45. Analysis of elevated serum interleukin-6 levels in rheumatoid arthritis: Correlation with erythrocyte sedimentation rate or C-reactive protein
46. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis
47. Imbalance in production between vascular endothelial growth factor and endostatin exists in patients with rheumatoid arthritis